摘要
目的:比较阿立哌唑与利培酮对首发精神分裂症患者的疗效和安全性。方法:100例首发分裂症患者随机分为两组,分别进行为期12周的阿立哌唑治疗和利培酮治疗,评定工具包括阳性与阴性症状量表(PANSS,在治疗前及治疗后2、4、6、8、12周末评定)及治疗副反应量表(TESS,治疗后2、4、6、8、12周末评定),使用PANSS减分率评定疗效。结果:与基线相比,两组患者的PANSS评分在治疗后各观察点均显著降低(P均<0.05),治疗后各观察点的PANSS总分及减分率在两组间,差异无统计学意义(P均>0.05);两组在治疗终点的总体疗效差异无统计学意义(χ2=0.723,P=0.728);两组总体副反应发生率差异无统计学意义(χ2=1.288,P=0.256),但治疗后4、6、8、12周末,利培酮组的TESS评分显著高于阿立哌唑组(P均<0.05)。结论:阿立哌唑对首发精神分裂症的疗效与利培酮相当,但其副作用严重程度和持续时间要轻于利培酮。
Objective： To compare the efficacy and safety between aripiprazole and risperidone in the treatment of firstepisode schizophrenia.Methods： 100 first-episode schizophrenic patients were randomized into two groups treated with aripiprazole or risperidone for 12 weeks.Evaluation measures included positive and negative symptom scale（PANSS,evaluated at baseline,2nd weekend,4th weekend,6th weekend,8th weekend,12nd weekend） and treatment emergent symptom scale（TESS,evaluated at 2nd weekend,4th weekend,6th weekend,8th weekend,12nd weekend）.The reduction rate of PANSS score was used to evaluate the overall efficacy.Results： Compared with baseline,PANSS total score of each group decreased significantly at each observation point（P0.05）.No significant differences were found between the two groups in total score and reduction rate of PANSS at each observation point（P0.05）.There was no significant difference in overall effi cacy between the two group at the end of treatment（χ2=0.723,P=0.728）.No significant difference was found between the two groups in overall adverse reaction rate（χ2=1.288,P=0.256）,however,TESS score in risperidone group was significant higher than in aripiprazole group at 4th weekend,6th weekend,8th weekend and 12nd weekend（P0.05）.Conclusion： The efficacy of aripiprazole for first-episode schizophrenia is equivalent to risperidone,but side effect severity and persistence of aripiprazole is fewer than risperidone.
出处
《中国当代医药》
2010年第22期37-39,共3页
China Modern Medicine
